TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03160547

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Protein/Amino Acid Group
Description: Protein targets will be set using pre-ICU dry actual weight. For patients with BMI \>30, ideal body weight based on a BMI of 25 will be used. We will endorse the guidelines for energy targets set forth by ASPEN/SCCM, especially as it pertains to the obese patient.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Higher Protein/Amino Acid Group
Description: Protein targets will be set using pre-ICU dry actual weight. For patients with BMI \>30, ideal body weight based on a BMI of 25 will be used. We will endorse the guidelines for energy targets set forth by ASPEN/SCCM, especially as it pertains to the obese patient.
Study: NCT04652414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone 50mg will be administered enterally for 7 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This is a matching placebo to prednisone.
Study: NCT03010436

Intervention type: DRUG
Group type: OTHER
Intervention: Benralizumab
Description: one injection 30 mg under the subjects skin every 4 weeks for 8 weeks and then every 8 weeks for 24 weeks for a total of 5 treatments.
Study: NCT03893253

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Booster Teaching
Description: The early booster group will receive a booster teaching session at 3 weeks post-training followed by feedback.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Late Booster Teaching
Description: The late booster group will receive a booster teaching session at 2 months post-training followed by feedback
Study: NCT02293109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carfilzomib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV or PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03026387

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Neuropsychological battery tests
Description: The neuropsychological battery tests is composed with: Continuous Performance Test, Iowa Gambling Test, Verbal fluency (animals), Emotional stroop, Self-injury implicit association test and N-back test.~The neuropsychological battery assesses domains heavily involved in suicidal behavior: impulsivity, affective dysregulation, alterations in decision-making (risky choices), selective attention,verbal fluidity and working memory.
Study: NCT01244620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitaxentan
Description: sitaxsentan 100 mg QD for 6 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tadalafil
Description: tadalafil 40 mg QD for 6 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitaxsentan
Description: sitaxsentan 100 mg QD for 6 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tadalafil
Description: tadalafil 40 mg QD for 6 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitaxsentan
Description: sitaxentan 100 mg QD for 6 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sildenafil
Description: sildenafil 20 mg TID for 6 days
Study: NCT02773134

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Brace Group
Description: All eligible patients will undergo a Posterior Spine Instrumented Fusion (PSIF) with the use of autologous local and iliac crest bone graft, and all pedicle screw instrumentation. A deep wound drain will be placed in all patients for 48 hours.~All patients will complete the Oswestry Disability Index (ODI) questionnaire, the SF-12v2 General Health Survey and the Visual Analogue Scale (VAS) for back pain at baseline visit (preoperatively) and post-operatively at 6 weeks and 3 months follow up. Clinical and radiographic assessments will be performed by independent blinded observers not involved in patient care.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Group
Description: All eligible patients will undergo a Posterior Spine Instrumented Fusion (PSIF) with the use of autologous local and iliac crest bone graft, and all pedicle screw instrumentation. A deep wound drain will be placed in all patients for 48 hours.~Bracing will not be prescribed postoperatively for this group. All patients will the Oswestry Disability Index (ODI) questionnaire, the SF-12v2 General Health Survey and the Visual Analogue Scale (VAS) for back pain at baseline visit (pre-operatively) and post-operatively at 6 weeks and 3 months follow up. Clinical and radiographic assessments will be performed by independent blinded observers not involved in patient care.
Study: NCT00725517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icodextrin
Description: Icodextrin was used instead of Dianeal for long dwell time every day for 5 weeks.
Study: NCT01959750

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: problem-based sessions
Description: weekly sessions for small groups of caregivers, led by two psychologists acting as moderators and using a systemic approach, as suggested in other peer-support groups using a problem-based method
Study: NCT03199547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: The women will be randomized to receive a single dose of Azithromycin or Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: The women will be randomized to receive a single dose of Azithromycin or Placebo
Study: NCT01813175

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Regular non-hydrolysed cow's milk I
Description: Regular non-hydrolysed cow's milk based infant formula with synbiotics mixture I
Study: NCT03815279

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Carfilzomib will be administered intravenously three times per cycle (28 day cycles) for cycle 1-12. Thereafter twice per cycle for cycle 13-24

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide PO once daily on days 1-21 of a 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide PO once daily on days 1-21 of a 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be administered weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be administered weekly
Study: NCT02498847

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ENGAGE
Description: Participants are introduced to ENGAGE program by the study OT. The ENGAGE program is located on a website and has several modules. The modules include a video in which a health provider is featured. This health provider gives a short presentation on a topic related to OA, symptom management or lifestyle change. Within each module, there is downloadable homework and additional information which can be printed. The modules are:~* What is Osteoarthritis?~* Information about treatments~* Exercise~* Sleep hygiene~* Relaxation~* Pleasant Activity Scheduling~* Goal setting~* Problem Solving~* Pacing~* Communication
Study: NCT02640599

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vestibular Rehabilitation + Aerobic Exercise
Description: Subjects in the experimental group will undergo traditional Vestibular Rehabilitation as well as participate in an aerobic exercise training program.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vestibular Rehabilitation
Description: The control group will receive standard care which includes participation in vestibular physical therapy treatments 1-2 times per week.
Study: NCT01428921

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Theory based education and brief motivation interview
Description: * Standard education programme as described above,~* Plus~  1. Face-to-face session (Part 1: Knowledge Enhancement Session, Part 2: Brief Motivation Interview Session) after the morning of CPAP titration~ 2. Follow-up phone call would be arranged within 1 week after using CPAP.~ 3. Video, slides and booklets would be used as education media.
Study: NCT02468193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osilodrostat
Description: Osirodrostat 1mg, 5mg \& 10mg in the form of film-coated tablets was used for oral administration.
Study: NCT00775164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pioglitazone
Description: 15 mg per day for 4 weeks, then up-titrated to 30 mg per day for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin XR; 1000 mg once daily
Study: NCT01306981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Intravitreal injection of ranibizumab, 0.5mg in 0.05ml

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Subconjunctival injection of 0.05ml saline 0.9% w/v
Study: NCT04032977

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PN40082
Description: To provide a 1-point improvement in the lip fullness grading scale score of subjects with very thin or thin lips or subjects with Fitzpatrick IV, V or VI to improve the LFGS score by 1 for 1 or both lips

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PN40082
Description: To provide a 1-point improvement in the lip fullness grading scale score of subjects with very thin or thin lips or subjects with Fitzpatrick IV, V or VI to improve the LFGS score by 1 for 1 or both lips

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane Silk
Description: To provide a 1-point improvement in the lip fullness grading scale score of subjects with very thin or thin lips or subjects with Fitzpatrick IV, V or VI to improve the LFGS score by 1 for 1 or both lips

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Restylane Silk
Description: To provide a 1-point improvement in the lip fullness grading scale score of subjects with very thin or thin lips or subjects with Fitzpatrick IV, V or VI to improve the LFGS score by 1 for 1 or both lips
Study: NCT02159950

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sipuleucel-T
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sipuleucel-T
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tasquinimod
Description: Given PO
Study: NCT00678639

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Observation unit care, coupled with cardiac MRI
Description: After Emergency Department (ED) evaluation, patients are randomized to Observation unit care or standard inpatient care. Patients in the observation unit will also undergo a stress cardiac MRI. Patients in the usual care arm may undergo any desired testing, including cardiac MRI, as determined by their treating physician.
Study: NCT03893318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV lidocaine
Description: an amide-type, short-acting local anesthetic and delivered as an aqueous solution for intravenous administration. It has a half-life of 1.5-2 hours. A traditional method of administration is via epidural delivery. Epidural lidocaine is effective and this effect is due, in part, to systemic absorption. Systemic (intravenous) administration of lidocaine is a Food and Drug Administration approved method of delivery. Low plasma levels are needed for effective use, 0.5µg/mL to 5.0µg/mL. Given this low concentration required and the short half-life, continuous infusion of lidocaine is thought to be generally safe with low risk of complication.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Saline
Study: NCT00974740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: atorvastatin 40 mg (tablet for oral intake) once daily in the evening for 4 weeks, thereafter 80 mg for the remaining treatment period (total treatment period 18 months)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: atorvastatin matching placebo
Description: atorvastatin matching placebo tablets once daily in the evening, corresponding to 40 mg atorvastatin for the first 4 weeks (run-in period), and corresponding to 80 mg atorvastatin thereafter (total treatment period 18 months)
Study: NCT03423680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abilify 2, 5, 10, 15mg (Tablet)
Description: Randomized subjects will take 1 tablet of aripiprazole or placebo orally once daily from the baseline visit (Visit 2) to Visit 8 (Week 8 visit or discontinuation visit). The initial dose of aripiprazole, the investigational product, is 2 mg once daily (irrespective of meals), which the investigators can maintain, increase or decrease within a range of 2 - 15 mg at each scheduled study visit, depending on the subject's clinical response and tolerability.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of Abilify 2, 5, 10, 15mg (Tablet)
Description: Randomized subjects will take 1 tablet of aripiprazole or placebo orally once daily from the baseline visit (Visit 2) to Visit 8 (Week 8 visit or discontinuation visit). The initial dose of aripiprazole, the investigational product, is 2 mg once daily (irrespective of meals), which the investigators can maintain, increase or decrease within a range of 2 - 15 mg at each scheduled study visit, depending on the subject's clinical response and tolerability.
Study: NCT03125473

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VXA-G1.1-NN Oral Vaccine
Description: The drug product will be provided as small white enteric-coated tablets. Multiple tablets will be administered to deliver the high total doses.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VXA-G1.1-NN Oral Vaccine
Description: The drug product will be provided as small white enteric-coated tablets. Multiple tablets will be administered to deliver the high total doses.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VXA-G1.1-NN Oral Vaccine
Description: The drug product will be provided as small white enteric-coated tablets. Multiple tablets will be administered to deliver the high total doses.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VXA-G1.1-NN Oral Vaccine
Description: The drug product will be provided as small white enteric-coated tablets. Multiple tablets will be administered to deliver the high total doses.
Study: NCT02729714

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Suvorexant
Description: 10 mg Suvorexant or matching Placebo orally at bedtime with optional up-titration to 15 mg Suvorexant or matching Placebo orally at bedtime after 2 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Suvorexant
Description: 10 mg Suvorexant or matching Placebo orally at bedtime with optional up-titration to 15 mg Suvorexant or matching Placebo orally at bedtime after 2 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10 mg Suvorexant or matching Placebo orally at bedtime with optional up-titration to 15 mg Suvorexant or matching Placebo orally at bedtime after 2 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 10 mg Suvorexant or matching Placebo orally at bedtime with optional up-titration to 15 mg Suvorexant or matching Placebo orally at bedtime after 2 weeks.
Study: NCT06074289

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family connections program
Description: Caregivers meet weekly for 90 minute sessions led by two trained psychologists. The program includes six modules: 1. Introduction, 2. Family Education, 3. Relationship Mindfulness Skills, 4. Family Environment Skills, 5. Validation Skills, 6. Problem Management Skills.
Study: NCT02909907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin
Description: Botulinum injections into dominant upper extremity using protocol outlined above.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin
Description: Botulinum injections into dominant upper extremity using protocol outlined above.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo injections in extensor carpi radialis (ECR) and extensor carpi ulnaris (ECU) per protocol outlined above
Study: NCT01888822

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin
Description: Prophylactic ciprofloxacin infusion before elective laparoscopic cholecystectomy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ampicillin-sulbactam
Description: Prophylactic ampicillin-sulbactam infusion before elective laparoscopic cholecystectomy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Prophylactic placebo infusion before elective laparoscopic cholecystectomy
Study: NCT01889498

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetazolamide
Description: Acetazolamide twice a day, at 12 hour intervals:~* 250 mg Tablets; one tablet to be taken twice daily from three days before the day of surgery~* One tablet to take two hours before surgery~* 500mg Intravenous Acetazolamide; to be administered upon arrival in critical care post-surgery; continuing at 12 hour intervals until last acetazolamide administration at 72 hours.
Study: NCT04197765

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: accelerated Thetaburst stimulation
Description: We will administer 20-30 treatment sessions over the course of the study. The study technician will place the coil over the Fp2 electrode of a 10-20 International EEG system hair net, to approximate stimulation of the R-OFC). For the first three treatments, the study psychiatrist will set treatment intensity to 90% MT, and gradually increase intensity to 120% MT over 20 seconds to maximize tolerability. Subsequent treatment sessions (treatment 4 and onward) will begin, and remain, at 120% MT.~Treatment will occur 4-5 times a day, separated by an at least 45-min interval between sessions on consecutive weekdays. We estimate all study-related treatments will be complete in 5-6 weekdays.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator
Description: All parameters will be programmed in the same way as active treatment, however, the treatment will be delivered on the side of the coil that has an internal (hidden) metal shield that will prevent magnetic energy from reaching the skull and brain. Neither the technician, treating physician, nor the patient, will know whether the treatment was delivered from the sham or active side of the coil. The same auditory and tactile cues will be present during active and sham treatment as electrodes will be placed on the scalps of each participant (whether receiving active or sham treatment) that deliver some electrical sensation.
Study: NCT02982356

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Fetal Selective Reduction Technology
Description: Fetal Selective Reduction Technology will be conducted according to different gestational weeks: before 16weeks, 16\~24 weeks, 24\~27+6 weeks,\>28weeks

Intervention type: DRUG
Group type: OTHER
Intervention: Potassium Chloride
Study: NCT05742971

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality intervention performed through the Oculuc Go VR glasses
Description: The participants randomised into this group are offered a VR intervention during the external version for 5-10 minutes in addition to the standard care of an ECV. The VR is performed through the Oculus Go VR glasses. These women can choose for an immersive guided relaxation VR experience or an interactive VR experience (see descriptions below). The ECV expert executing the ECV will register immediately after the ECV which option the patients has chosen. Immediately after the external version, a pain measurement is taken with regard to the pain during the ECV by means of the NRS score. After the ECV procedure, participants of the VR-group receive a structured questionnaire in which tolerability, feasibility and satisfaction of VR use is evaluated.
Study: NCT00685477

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Experimental Sequence ABC
Description: Drug will be given over 15 minutes, followed by infusion over 30 minutes, followed by infusion over 60 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Experimental Sequence ACB
Description: Drug infused over 15 minutes, followed by infusion over 60 minutes, followed by infusion over 30 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Experimental Sequence BAC
Description: Drug will be given over 30 min infusion, followed by 15 minute infusion, followed by 60 minute infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Experimental Sequence BCA
Description: Drug will be given over 30 min infusion, followed by 60 minute infusion, followed by 15 minute infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Experimental Sequence CAB
Description: Drug will be given over 60 min infusion, followed by 15 minute infusion, followed by 30 minute infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Experimental Sequence CBA
Description: Drug will be given over 60 min infusion, followed by 30 minute infusion, followed by 15 minute infusion
Study: NCT04222881

Intervention type: PROCEDURE
Intervention: AVF anastomosis
Description: Type of arteriovenous anastomosis
Study: NCT02402738

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpersonal and Social Rhythm Therapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Treatment as Usual